TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection

Blood

Volumn 112, Issue 8, 2008, Pages 3508-3516

  Taylor, Patricia A ^a   Ehrhardt, Michael J ^a   Lees, Christopher J ^a   Panoskaltsis Mortari, Angela ^a   Krieg, Arthur M ^b   Sharpe, Arlene H ^c   Murphy, William J ^d   Serody, Jonathan S ^e   Hemmi, Hiroaki ^e   Akira, Shizuo ^f   Levy, Robert B ^g   Blazar, Bruce R ^a,h  

^a Division of Global Pediatrics   (United States)

^b PFIZER INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f OSAKA UNIVERSITY   (Japan)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CELL COUNT; CONTROLLED STUDY; EFFECTOR CELL; ENGRAFTMENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; INTERFERON PRODUCTION; LYMPHOID ORGAN; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CYTOLOGY; DRUG POTENTIATION; IMMUNE SYSTEM; METABOLISM; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIGEN-PRESENTING CELLS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; IMMUNE SYSTEM; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-6; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TOLL-LIKE RECEPTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 54049153247     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113670     Document Type: Article

References (52)

1. Ahonen CL, Gibson SJ, Smith RM, et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol. 1999;197:62-72.
2. Ballas ZK, Rasmussen WL Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157:1840-1845.
3. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237-9242.
4. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065-6073.
5. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168: 4531-4537.
6. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
7. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
8. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000;12:35-43.
9. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 2003;9:831-835.
10. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
11. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31:3026-3037.
12. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007;19: 268-274.
13. Liu HM. Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:3730-3736.
14. Merad M, Sugie T, Engleman EG, Fong L. Invivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002;99:1676-1682.
15. Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol. 2004;172:6281-6289.
16. Roda JM, Parihar R, Carson WE III. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005; 175:1619-1627.
17. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol. 2000;30:3591-3597.
18. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368.
19. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186:1623-1631.
20. Ishii KJ, Akira S. Innate immune recognition of, and regulation by, DNA. Trends Immunol. 2006: 27:525-532.
21. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20: 709-760.
22. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31:2154-2163.
23. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as Thelper-1-promoting adjuvants. Nat Med. 1997; 3:849-854.
24. Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol. 2006;25:183-213.
25. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184-1194.
26. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001;98:1217-1225.
27. Hammerbeck DM, Burleson GR, Schuller CJ, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007;73:1-11.
28. Taylor PA, Ehrhardt MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood. 2007;109:1307-1315.
29. Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graftversus-host reactive T cells to peripheral tissues. J Exp Med. 2006;203:2021-2031.
30. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002; 420:329-333.
31. Yamamoto M, Sato S, Hemmi H, et al. Essential role forTIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002; 420:324-329.
32. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007;35:1461-1467.
33. Dudek AZ, Yunis C, Harrison LI, et al. First in human phase I trial of 852A, a novel systemic tolllike receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007;13:7119-7125.
34. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
35. Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother. 2007;56:1133-1141.
36. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem. 2007;141: 137-145.
37. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269.
38. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008;21:69-87.
39. Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem. 2007;14:681-687.
40. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27:190-199.
41. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
42. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172: 7393-7398.
43. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10:510-517.
44. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
45. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581.
46. Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest. 2002;109:1335-1344.
47. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol. 2002;169:7111-7118.
48. Amlie-Lefond C, Paz DA, Connelly MP, Huffnagle GB, Whelan NT, Whelan HT. Innate immunity for biodefense: a strategy whose time has come. J Allergy Clin Immunol. 2005;116:1334-1342.
49. Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther. 2007;9:45-52.
50. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999;11:123-129.
51. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol. 2006;311:155-178.
52. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997;94:10833-10837.